A Phase Ib/II Clinical Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer
Phase of Trial: Phase I/II
Latest Information Update: 23 Oct 2017
At a glance
- Drugs Amcasertib (Primary) ; Capecitabine; Doxorubicin; Nivolumab; Paclitaxel; Pembrolizumab; Sunitinib
- Indications Cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Boston Biomedical
- 13 Oct 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Mar 2018.
- 13 Oct 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov
- 03 Sep 2015 Planned primary completion date changed from 1 Aug 2017 to 1 Sep 2017 as reported by ClinicalTrials.gov record.